Research progress in TACE-based combination therapy for primary hepatocellular carcinoma
10.3969/j.issn.1008-794X.2024.06.020
- VernacularTitle:基于TACE联合治疗原发性肝细胞癌的研究进展
- Author:
Zhengfang XIAO
1
;
Youbing ZHENG
;
Feiyan DENG
;
Siqian ZHENG
;
Hongwei SUN
;
Yanyan LIU
;
Ligong LU
Author Information
1. 519000 广东珠海 暨南大学附属珠海医院(珠海市人民医院),广东省肿瘤介入诊疗重点实验室
- Keywords:
hepatocellular carcinoma;
hepatic arterial chemoembolization;
perfusion chemotherapy;
targeted therapy;
immunotherapy;
combination therapy
- From:
Journal of Interventional Radiology
2024;33(6):688-692
- CountryChina
- Language:Chinese
-
Abstract:
Liver cancer is a prevalent and highly malignant cancer worldwide,with 90％of cases being hepatocellular carcinoma,presenting a significant risk to human health.As early-stage liver cancer often lacks specific manifestations,most patients with liver cancer are already in the middle and late stage of the disease when liver cancer is diagnosed,thus,missing the opportunity for optimal radical treatment.However,the exploration of the treatment for middle and advanced primary hepatocellular carcinoma has never ceased.In recent years,transarterial chemoembolization(TACE)has been included in the standard treatment regimens for primary hepatocellular carcinoma.With the advancement of multidisciplinary comprehensive treatment,various treatment options to reduce the burden of liver cancer lesion with satisfactory therapeutic results have been reported and have been widely used in clinical practice,e.g.hepatic artery infusion chemotherapy(HAIC),targeted therapy,and immunotherapy in combination with TACE,which have significantly improved the overall survival of patients with liver cancer.This paper aims to make a comprehensive review about the latest progress of combination use of TACE and other therapies in reducing tumor burden and improving patient survival in the treatment of primary hepatocellular carcinoma,and to summarize the key issues in combination therapy that require more in-depth research.(J Intervent Radiol,2024,33:688-692)
